XBI - SPDR S&P Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
92.44
+0.23 (+0.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close92.21
Open91.71
Bid0.00 x 4000
Ask0.00 x 1100
Day's Range91.70 - 93.23
52 Week Range66.66 - 97.98
Volume4,240,479
Avg. Volume4,484,114
Net Assets4.92B
NAV86.90
PE Ratio (TTM)N/A
Yield0.28%
YTD Return2.55%
Beta (3y)1.84
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • MarketWatch10 days ago

    President Trump’s big drug price speech boosts pharma stocks

    After weeks of build-up, drug industry watchers began to have real concerns about President Donald Trump’s big drug price speech on Friday. Many of the changes that were mentioned on Friday had been raised before by his administration, including drug price negotiation for certain government programs. Other proposals seemed unlikely to significantly bring down drug prices in the near-term, which Trump described as a goal of the plan.

  • ETF Trends13 days ago

    6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’

    Healthcare stocks and top healthcare ETFs rallied Friday after President Donald Trump vowed to end to "global freeloading" that has allowed foreign countries to pay less on American-manufactured medicines. The Health Care Select Sector SPDR (XLV), the largest healthcare exchange traded fund, gained 1.5% Friday while the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, rose 2.7% and VanEck Vectors Generic Drugs ETF (GNRX) , which focuses on generic drug producers, added 2.2%.

  • Investopedialast month

    Biotech Stocks Face a Steep Drop

    An analysis of Biotech ETF XBI's chart suggests the sector could be set for a decline of over 8%.

  • ETF Databaselast month

    Trending: Investors Apathetic to Barclays' $1.2 Billion ETN Shutoff

    This week, investors were preoccupied with Russia, as the country’s equities fell dramatically after the relations with countries in the West, including the U.S., deteriorated. First in the list, however, is Barclays Capital, as the asset management arm of the British bank said it would shut down a host of exchange-traded notes (ETNs). Russia is second in the list followed by crude oil, which has been on a tear lately thanks to dropping stockpiles in the U.S. Leveraged ETFs and biotechnology stocks close the list. Check our previous trends edition at Trending: Soybean Prices Whipsaw on Trade War Fears.

  • Why These Small Cap Biotech ETFs are Soaring
    Zackslast month

    Why These Small Cap Biotech ETFs are Soaring

    These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.

  • Barrons.comlast month

    Could Big Biotech Earnings Be a Bust?

    Singh's more conservative on Gilead Sciences (GILD), writing that its HIV drug Biktarvy is seeing a good launch, but not as strong Genvoya, and Regeneron Pharmaceuticals (REGN), where he sees a strong second half in terms of regulatory approvals as balanced by "burgeoning operating expenses and negative sentiment." He has Perform ratings on both stocks. Moving down the line, he's more bullish on mid- and small-cap biotechs, which are not only benefitting from M&A in the sector, but should also "continue to positively diverge from large-cap biotech" in first-quarter earnings results as well.

  • Barrons.comlast month

    Tech, Biotech Rife With Buys, M&A, Disruptive Trends

    Tom Vandeventer, portfolio manager of the Tocqueville Opportunity Fund (TOPPX), which is up nearly 10% so far this year, thinks that trend will continue. Tech and biotech are two major themes running through the fund’s portfolio, which Vandeventer told Barron’s is indicative of the fact that “there are a lot of disruptive technologies that are coming to fruition” in both sectors. The fund focuses more on small- and mid-cap stocks, meaning that M&A is a theme throughout his holdings, in both tech and biotech, bolstered by industry trends (the move to the cloud, the rise of gene-editing therapies, respectively), as well the fact that larger players are flush with cash—thanks to lower corporate taxes and repatriated capital—to facilitate acquisitions.

  • Barrons.comlast month

    Better Days Ahead for Big Biotechs

    The first quarter is traditionally not a strong one for biotech earnings for a host of reasons—including fewer shipping days, inventory reductions after year-end price increases, weather disruptions, and annual copay resets in many health insurance plans. The SPDR S&P Biotech ETF (XBI) is up 2.8% to $91.38 today, and the iShares Nasdaq Biotechnology ETF (IBB) is climbing 2.2% to $107.55.

  • Barrons.comlast month

    Bigger Biotechs Bound for Earnings Bounty

    Just as Barron's predicted, this year has seen smaller biotech stocks outperform their larger peers, with the SPDR S&P Biotech ETF (XBI) up 15% year-to-date, while the iShares Nasdaq Biotechnology ETF (IBB) has fallen 1.2%.  Now, as we gear up for first-quarter earnings in the sector, SunTrust Robinson Humphrey sees a number of potentially better-than-expected results ahead. The team, led by analyst Yatin Suneja, writes that investors appear "poised to reward companies with good financial performance." He believes that positive pricing trends, along with tailwinds from foreign exchange and moderate expectations on the Street can drive outperformance, even if seasonality is a headwind. Suneja thinks that among big biotechs, Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceuticals (BMRN), Celgene (CELG), Exelixis (EXEL), Regeneron Pharmaceuticals (REGN), and Sarepta Therapeutics (SRPT) have the best chance of reporting better-than-expected sales in the quarter, while he sees a more in-line quarters for Biogen (BIIB) and Incyte (INCY).

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realistlast month

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • Novartis Enters Agreement to Acquire AveXis
    Market Realistlast month

    Novartis Enters Agreement to Acquire AveXis

    On April 9, 2018, Novartis AG (NVS) announced that it had entered into an agreement to acquire AveXis (AVXS), a clinical-stage gene therapy company, for ~$8.7 billion. 

  • ETF Trendslast month

    Catalysts Abound for Biotech ETFs

    Biotechnology stocks and biotech ETFs tumbled in the back half of March and to start April. For example, the SPDR S&P Biotech ETF (NYSEArca: XBI) came into Monday with a loss of almost 12.6% over the past ...

  • Barrons.comlast month

    Biotech's Bounce Might Have Begun…Finally

    Biotechnology stocks and the exchange-traded funds that hold them have tried to rally in recent months, only to disappoint investors over and over again. "While nearly every index, ETF and stock finished noticeably below their respective highs, some still notched impressive net moves on Monday," wrote Instinet technical analyst Frank Cappelleri. "The [iShares Nasdaq Biotechnology ETF] was the leader among the industry ETFs we track, missing a 2% gain." Gene therapy company AveXis (AVXS) helped lead the way Monday, popping more than 80% to above $200 on news that drug juggernaut Novartis (NVS) planned to acquire it for $8.7 billion in cash or $218 per share.

  • Benzingalast month

    Mergers, Acquisitions And A Tax Cut: Why This Biotech ETF Can Rebound

    Biotechnology stocks and related exchange traded funds have been drubbed recently. Coming into Monday, the SPDR S&P Biotech ETF (NYSE: XBI ), one of the largest such ETFs, was sporting one-week and one-month ...

  • Barrons.com2 months ago

    Biotech Funds Still Bleeding Money

    It's a new quarter, but the same old trends are at play in terms of biotech fund flows, writes Raymond James's Laura Chico. For the week ending April 4, biotech funds saw $240 million in outflows, a 0.4% ...

  • ETF Trends2 months ago

    Alkermes FDA Refusal: Biotech ETFs Dragged Down

    Biotechnology stocks and biotech ETFs were among the worst performing areas of the markets Monday as Alkermes (NasdaqGS: ALKS) shares plunged after the U.S. food and Drug Administration refused to review ...

  • How Did Ionis’s Revenues Trend in 4Q17?
    Market Realist2 months ago

    How Did Ionis’s Revenues Trend in 4Q17?

    How Ionis Pharmaceuticals Is Positioned in 2018

  • Incyte’s Revenue Trends in 4Q17
    Market Realist2 months ago

    Incyte’s Revenue Trends in 4Q17

    Who’s Watching Incyte Corporation in March 2018?

  • Barrons.com2 months ago

    A Biotech Merger Wave Looms Despite Political Pitfalls

    Mergers have never been easy but these days companies have a new set of worries to add to the list. National security has become a potential hurdle after the potential merger of Broadcom (AVGO) and Qualcomm ...

  • The 4 Top Biotech ETFs
    Motley Fool2 months ago

    The 4 Top Biotech ETFs

    Investing in biotechnology has been very lucrative lately, and these funds can help you tap into the industry's success.

  • Benzinga2 months ago

    Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather'

    The broader market scuffled in February, but the health care sector was worse. For example, the Health Care Select Sector SPDR (NYSE: XLV ) lost 4.5 percent, which was about 80 basis points worse than ...

  • Benzinga3 months ago

    Height Securities: The Clock Is Ticking For Big Pharma As Congressional Spending Cuts Loom

    The pharmaceutical industry is lobbying to reverse part of the recent Congressional spending bill that shifted a $10-billion consumer aid burden from the federal government to manufacturers. The Bipartisan ...

  • Apple, Boeing Soar As Market Rallies; Bitcoin Ignores Warning
    Investor's Business Daily3 months ago

    Apple, Boeing Soar As Market Rallies; Bitcoin Ignores Warning

    Key market index funds extended their gains Monday as Apple and Boeing led the Dow Jones industrial average.

  • Investopedia3 months ago

    Biotech Stocks Trade Near Major Levels of Support

    With biotech stocks tumbling toward long-term levels of support, we take a closer look at how active traders will trade the bounce.